Varenicline enhances oxidized LDL uptake by increasing expression of LOX-1 and CD36 scavenger receptors through α7 nAChR in macrophages

Abstract Varenicline is a widely used and effective drug for smoking cessation. It is a partial agonist of the α4β2 nicotinic acetylcholine receptor (nAChR) and full agonist of α7 nAChR. We have reported that varenicline aggravates formation of atherosclerotic plaques through α7 nAChR in apolipoprot...

Full description

Saved in:

Bibliographic Details
Published in:	Toxicology (Amsterdam) Vol. 380; pp. 62 - 71
Main Authors:	Kanaoka, Yuki, Koga, Mitsuhisa, Sugiyama, Keita, Ohishi, Kaoru, Kataoka, Yasufumi, Yamauchi, Atsushi
Format:	Journal Article
Language:	English
Published:	Elsevier B.V 01-04-2017
Subjects:	Atherosclerosis Emergency oxLDL uptake Scavenger receptor Varenicline α7 nAChR ABC scavenger receptor MLA high-density lipoprotein oxLDL uptake cluster of differentiation 36 LOX-1 varenicline HDL NF-κB dihydro-β-erythroidine hydrobromide nAChR oxLDL CD36 scavenger receptor class A extracellular signal-regulated kinase 1/2 nicotinic acetylcholine receptor atherosclerosis α 7 nAChR nuclear factor-kappa B lectin-like oxidized LDL receptor-1 methyllycaconitine ERK1/2 SR-A adenosine triphosphate-binding cassette transporters DHβE oxidized low-density lipoprotein Scavenger receptor Varenicline α7 nAChR Atherosclerosis
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!